Malaria is a devastating disease caused by Plasmodium parasites. Emerging resistance
against current antimalarial therapeutics has engendered the need to develop antimalarials …

Novel antimalarial therapeutics that target multiple stages of the parasite lifecycle are
urgently required to tackle the emerging problem of resistance with current drugs. Here, we …

Discovery of novel effective and safe antimalarials has been traditionally focused on
targeting erythrocytic parasite stages that cause clinical symptoms. However, elimination of …

Quinoline-based scaffolds have been the mainstay of antimalarial drugs, including many
artemisinin combination therapies (ACTs), over the history of modern drug development …

Malaria is a devastating parasitic disease caused by parasites from the genus Plasmodium.
Therapeutic resistance has been reported against all clinically available antimalarials …

A novel class of benzoheterocyclic analogues of amodiaquine designed to avoid toxic
reactive metabolite formation was synthesized and evaluated for antiplasmodial activity …

Utilizing mefloquine as a scaffold, a next generation quinoline methanol (NGQM) library was
constructed to identify early lead compounds that possess biological properties consistent …

The continued proliferation of malaria throughout temperate and tropical regions of the world
has promoted a push for more efficacious treatments to combat the disease. Unfortunately …

Abstract 4 (1H)-quinolone is an attractive template for antimalarial drug discovery
campaigns. Given the current global increase in drug and insecticide resistance, the …

Malaria deaths have been decreasing over the last 10–15 years, with global mortality rates
having fallen by 47% since 2000. While the World Health Organization (WHO) recommends …